265 related articles for article (PubMed ID: 38620635)
1. A review of the COVID-19 pandemic and its interaction with environmental media.
Muthuraman Y; Lakshminarayanan I
Environ Chall (Amst); 2021 Apr; 3():100040. PubMed ID: 38620635
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 in environmental perspective: Occurrence, persistence, surveillance, inactivation and challenges.
Mohan SV; Hemalatha M; Kopperi H; Ranjith I; Kumar AK
Chem Eng J; 2021 Feb; 405():126893. PubMed ID: 32901196
[TBL] [Abstract][Full Text] [Related]
3. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
4. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
[TBL] [Abstract][Full Text] [Related]
5. Current Strategies of Antiviral Drug Discovery for COVID-19.
Mei M; Tan X
Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
[TBL] [Abstract][Full Text] [Related]
6. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
7. Occurrence, fates and potential treatment approaches for removal of viruses from wastewater: A review with emphasis on SARS-CoV-2.
Bhatt A; Arora P; Prajapati SK
J Environ Chem Eng; 2020 Oct; 8(5):104429. PubMed ID: 32895629
[TBL] [Abstract][Full Text] [Related]
8. Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?
Elrashdy F; Redwan EM; Uversky VN
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32933047
[TBL] [Abstract][Full Text] [Related]
9. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Alnefaie A; Albogami S
Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
[TBL] [Abstract][Full Text] [Related]
10. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
11. Bioactive natural compounds against human coronaviruses: a review and perspective.
Xian Y; Zhang J; Bian Z; Zhou H; Zhang Z; Lin Z; Xu H
Acta Pharm Sin B; 2020 Jul; 10(7):1163-1174. PubMed ID: 32834947
[TBL] [Abstract][Full Text] [Related]
12. A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
Noor R
Arch Microbiol; 2021 Jul; 203(5):1943-1951. PubMed ID: 33682075
[TBL] [Abstract][Full Text] [Related]
13. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y
Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119
[TBL] [Abstract][Full Text] [Related]
14. Present cum future of SARS-CoV-2 virus and its associated control of virus-laden air pollutants leading to potential environmental threat - A global review.
Mukherjee S; Boral S; Siddiqi H; Mishra A; Meikap BC
J Environ Chem Eng; 2021 Apr; 9(2):104973. PubMed ID: 33462561
[TBL] [Abstract][Full Text] [Related]
15. Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19).
Tizaoui K; Zidi I; Lee KH; Ghayda RA; Hong SH; Li H; Smith L; Koyanagi A; Jacob L; Kronbichler A; Shin JI
Int J Biol Sci; 2020; 16(15):2906-2923. PubMed ID: 33061805
[TBL] [Abstract][Full Text] [Related]
16. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines.
Müller MA; Raj VS; Muth D; Meyer B; Kallies S; Smits SL; Wollny R; Bestebroer TM; Specht S; Suliman T; Zimmermann K; Binger T; Eckerle I; Tschapka M; Zaki AM; Osterhaus AD; Fouchier RA; Haagmans BL; Drosten C
mBio; 2012 Dec; 3(6):. PubMed ID: 23232719
[TBL] [Abstract][Full Text] [Related]
17. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.
Wu Z; Harrich D; Li Z; Hu D; Li D
Rev Med Virol; 2021 Mar; 31(2):e2171. PubMed ID: 33350025
[TBL] [Abstract][Full Text] [Related]
18. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
19. Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2.
da Silva PG; Mesquita JR; de São José Nascimento M; Ferreira VAM
Sci Total Environ; 2021 Jan; 750():141483. PubMed ID: 32829257
[TBL] [Abstract][Full Text] [Related]
20. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
